With the slowdown in world economic growth, the Biopharmaceutical Buffers industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Biopharmaceutical Buffers market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2018, Stratagem Market Insights analysts believe that in the next few years, Biopharmaceutical Buffers market size will be further expanded, we expect that by 2023, The market size of the Biopharmaceutical Buffers will reach XXX million $.
A buffer solution contains a weak conjugate acid-base pair. It may contain a weak acid and its conjugate base or a weak base and its conjugate acid. Biopharmaceutical buffers find application in protein-based drugs as many proteins are highly sensitive to pH and other environmental factors. Addition of buffers aids to limit changes in pH.
Increasing development of biopharmaceuticals is expected to propel growth of the global biopharmaceutical buffers market over the forecast period. For instance, according to Pharmaceutical Research and Manufacturers of America, over 750 orphan drugs were approved in the U.S. in 2018, compared to over 600 in 2017.
The market is witnessing increasing approval and launch of biopharmaceuticals, which is boosting growth of the market. For instance, in August 2018, the U.S. Food and Drug Administration approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.
Increasing prevalence of chronic disorders is expected to offer lucrative growth opportunities for players in the global biopharmaceutical buffers market. For instance, according to the study, “Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017”, published in the journal Annals of the Rheumatic Diseases, in November 2019, the age-standardized point prevalence and annual incidence rates of rheumatoid arthritis were 246.6 and 14.9 in 2017, which increased by 7.4% and 8.2% from 1990, respectively.
However, use of buffers presents complexities in manufacturing of biopharmaceutical drugs, which is expected to hinder growth of the global biopharmaceutical buffers market. Buffer solutions used in biopharmaceutical manufacturing are very dilute and require large storage facilities, which increases labor cost and required space.
Major players in the market are focused on launching new products to expand their product portfolio. For instance, in April 2019, MilliporeSigma launched its BioContinuum Buffer Delivery Platform, a new building block in the BioContinuum Platform for next-generation bioprocessing, at INTERPHEX in New York City, U.S.
Key Takeaways
Increasing development of biopharmaceuticals to augment growth of the global biopharmaceutical buffers market over the forecast period
Major players in the market are focused on adopting collaboration strategies to enhance their market share. For instance, in November 2019, Avantor, Inc. collaborated with National Institute for Bioprocessing Research and Training, Ireland, to address downstream issues with buffer preparation when producing monoclonal antibodies.
Major players operating in the global biopharmaceutical buffers market include, GE Healthcare, Thermo Fisher Scientific, Avantor, Inc., Danaher Corporation, Sartorius StedimBiotech, MilliporeSigma (Merck KGaA), Eppendorf, Roche, Nova Biomedicals, Lonza, Becton, and Dickinson and Company, and GEA
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.
Section 1: Definition
Section (2 3): Manufacturer Detail
GE Healthcare
Thermo Fisher Scientific
Danaher Corporation
Sartorius StedimBiotech
Merck
Eppendorf
Roche
Nova Biomedicals
Lonza
Becton, and Dickinson and Company
GEA
Section 4: Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7):
Product Type Segmentation
Sterile Buffer
Non-sterile Buffer
Industry Segmentation
Recombinant Proteins
Monoclonal Antibodies
Antibiotics
Probiotics
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2018-2023)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
